Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
| ▸ | GLP1R | P43220 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13014750 | 1.00 | APLNR (0.37) | APLNRADORA1GLP1RMEN1GAA | |
| SCHEMBL15757814 | 0.97 | ADORA1 (0.38) | APLNRADORA1GLP1RMEN1GAA | |
| SCHEMBL12143361 | 0.92 | APLNR (0.42) | APLNRADORA1MEN1GAAKMT2A | |
| SCHEMBL23818338 | 0.89 | TDP1 (0.43) | APLNRADORA1MEN1GAAKMT2A | |
| SCHEMBL9971647 | 0.89 | MEN1 (0.44) | ADORA1GLP1RMEN1GAAKMT2A | |
| SCHEMBL13077420 | 0.89 | MEN1 (0.44) | ADORA1GLP1RMEN1GAAKMT2A | |
| SCHEMBL3486898 | 0.89 | MEN1 (0.44) | ADORA1GLP1RMEN1GAAKMT2A | |
| SCHEMBL29679063 | 0.89 | MEN1 (0.44) | ADORA1GLP1RMEN1GAAKMT2A | |
| SCHEMBL11988183 | 0.88 | APLNR (0.35) | APLNRADORA1MEN1GAAKMT2A | |
| SCHEMBL14258504 | 0.87 | ADORA1 (0.37) | APLNRADORA1GLP1RMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| EP-2268609-B1 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2009108484-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | COASY, DHPS, FASN | APLNR 226/4885ADORA1 4613/4885GLP1R 3094/4885 |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GAS6, LNPEP, BMP6 | APLNR 167/4885ADORA1 4534/4885GLP1R 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.